NEU 6.33% $20.27 neuren pharmaceuticals limited

The NDD box seat, page-14

  1. 2,159 Posts.
    lightbulb Created with Sketch. 526
    Retas Skyclavs was one of the biggest in 2023 for $7.3bn US by Biogen rare disease drug estimate 5,000 patients in US and $1.5bn sales 2030….. premium was only 60% on their share price at the time.

    2591 ‘s potential patients with only current x 4 indications is x 10 (as per presentations) that of Skyclavs with scope for many more potentially…..

    Retas deal x 10 is $10-15bn in sales 2030-2033 US only for the potential future of 2591 as a starting point. Likely $30 bn globally…

    Fairly attractive asset.


 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.27
Change
-1.370(6.33%)
Mkt cap ! $2.588B
Open High Low Value Volume
$21.62 $21.63 $20.24 $11.01M 531.9K

Buyers (Bids)

No. Vol. Price($)
2 1111 $20.26
 

Sellers (Offers)

Price($) Vol. No.
$20.28 338 1
View Market Depth
Last trade - 16.10pm 03/06/2024 (20 minute delay) ?
Last
$20.37
  Change
-1.370 ( 5.24 %)
Open High Low Volume
$21.61 $21.62 $20.25 138748
Last updated 15.59pm 03/06/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.